PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma

Xiaoman Li; Changjing Wu; Nianci Chen; Huadi Gu; Allen Yen; Liu Cao; Enhua Wang; Liang Wang

doi:10.18632/oncotarget.7961

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma

Xiaoman Li, Changjing Wu, Nianci Chen, Huadi Gu, Allen Yen, Liu Cao, Enhua Wang and Liang Wang _

PDF | HTML | How to cite

Oncotarget. 2016; 7:33440-33450. https://doi.org/10.18632/oncotarget.7961

Metrics: PDF 9014 views | HTML 13066 views | ?

Abstract

Xiaoman Li1,*, Changjing Wu1,*, Nianci Chen2, Huadi Gu3, Allen Yen4, Liu Cao1, Enhua Wang3,5 and Liang Wang3,5

1 Key Laboratory of Medical Cell Biology, Ministry of Education, China Medical University, Shenyang, China

2 Class 9 of the 97th Clinical Medicine of Seven-Year Program, China Medical University, Shenyang, China

3 Department of Pathology, The College of Basic Medical Sciences, China Medical University, Shenyang, China

4 School of Medicine, The University of Texas Southwestern Medical Center, Dallas, Texas, United States of America

5 Department of Pathology, The First Affiliated Hospital of China Medical University, Shenyang, China

* These authors have contributed equally to this work

Correspondence to:

Liang Wang, email:

Keywords: glioblastoma, EGFR, PI3K/Akt/mTOR pathway, targeted therapy

Received: December 05, 2015 Accepted: February 24, 2016 Published: March 07, 2016

Abstract

Glioblastoma multiform (GBM) is the most common malignant glioma of all the brain tumors and currently effective treatment options are still lacking. GBM is frequently accompanied with overexpression and/or mutation of epidermal growth factor receptor (EGFR), which subsequently leads to activation of many downstream signal pathways such as phosphatidylinositol 3-kinase (PI3K)/Akt/rapamycin-sensitive mTOR-complex (mTOR) pathway. Here we explored the reason why inhibition of the pathway may serve as a compelling therapeutic target for the disease, and provided an update data of EFGR and PI3K/Akt/mTOR inhibitors in clinical trials.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 7961

Publication Alerts

Post-Publication Promotion

Publication Discount

Reviews:

PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma

Abstract